期刊
CHEMBIOCHEM
卷 22, 期 12, 页码 2011-2031出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cbic.202000787
关键词
high-throughput screening; inhibitors; ligases
资金
- European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [813599]
- EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant) [875510]
The ubiquitylation machinery plays a key role in various biological processes and its dysregulation is associated with multiple diseases.
TRIM proteins, as a novel class of ligases for drug development, are gaining attention in the pharmaceutical field.
Understanding the current research progress and potential targeting options for single polypeptide RING E3 ligases can provide insights into their therapeutic potential for diseases.
The ubiquitylation machinery regulates several fundamental biological processes from protein homeostasis to a wide variety of cellular signaling pathways. As a consequence, its dysregulation is linked to diseases including cancer, neurodegeneration, and autoimmunity. With this review, we aim to highlight the therapeutic potential of targeting E3 ligases, with a special focus on an emerging class of RING ligases, named tri-partite motif (TRIM) proteins, whose role as targets for drug development is currently gaining pharmaceutical attention. TRIM proteins exert their catalytic activity as scaffolds involved in many protein-protein interactions, whose multidomains and adapter-like nature make their druggability very challenging. Herein, we give an overview of the current understanding of this class of single polypeptide RING E3 ligases and discuss potential targeting options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据